Recommendations for the assessment of progression in randomised cancer treatment trials
- 31 January 2009
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (2) , 281-289
- https://doi.org/10.1016/j.ejca.2008.10.042
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Individual patient data analysis to assess modifications to the RECIST criteriaEuropean Journal Of Cancer, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Sensitivity analysis of progression‐free survival with dependent withdrawalStatistics in Medicine, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- When You Look Matters: The Effect of Assessment Schedule on Progression-Free SurvivalJNCI Journal of the National Cancer Institute, 2007
- Improving the design of phase II trials of cytostatic anticancer agentsContemporary Clinical Trials, 2007
- Optimizing randomized phase II trials assessing tumor progressionContemporary Clinical Trials, 2007
- Analysis of progression‐free survival in oncology trials: some common statistical issuesPharmaceutical Statistics, 2007